Capital Project Delivery

The pandemic exposed a hard truth about America’s dependence on foreign pharmaceutical production. Over the past two decades, the drive to move manufacturing offshore to reduce costs left the nation vulnerable when global supply chains were disrupted.

Recognizing this as both a health and national security risk, the U.S. government is now actively supporting the return of pharmaceutical and biotechnology manufacturing to domestic soil. This shift has sparked the announcement of numerous large-scale capital projects across the country.

Across the capital projects landscape, one recurring challenge continues to surface: misalignment between owner corporate business objectives and engineering solutions. This disconnect has led to countless projects running over budget and missing key schedule milestones, costing organizations both time and credibility and deteriorating owner financial and other business drivers.